Literature DB >> 6850993

Enhancement by testosterone of dimethylnitrosamine carcinogenesis in lung, liver and kidney of inbred NZR/Gd female rats.

R F Noronha, C M Goodall.   

Abstract

The effect of androgenic treatments on single dose dimethylnitrosamine (DMN) carcinogenesis was studied in 60 female NZR/Gd inbred rats, 25 of which were intact and received DMN 20 mg/kg i.p. in one dose after 48 h starvation, while 35 received DMN combined with testosterone injections every 4 weeks beginning 15 days before or after DMN, and in 29 rats combined also with ovariectomy. Sixteen female rats underwent ovariectomy and received testosterone every 4 weeks with no DMN. There were also 107 untreated intact contemporaneous control female rats. A single dose of DMN induced alveologenic lung (16%), hepatocellular (24%) and kidney epithelial (44%) tumours in intact rats, and the incidences of lethal tumours at these sites were significantly enhanced by androgenic treatments following the carcinogen, most markedly in the kidney. Androgenic treatment given before DMN injection had no significant effect on kidney or liver tumour incidences, but the carcinogenic response in lung was still strongly enhanced.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6850993     DOI: 10.1093/carcin/4.5.613

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

1.  Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.

Authors:  J Pinski; A V Schally; G Halmos; K Szepeshazi; K Groot; K O'Byrne; R Z Cai
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

2.  Menstrual and reproductive factors and risk of lung cancer among Chinese women, Eastern Gansu Province, 1994-1998.

Authors:  Alina V Brenner; Zuoyuan Wang; Ruth A Kleinerman; Shujie Lei; Catherine Metayer; Wenlan Wang; Jay H Lubin
Journal:  J Epidemiol       Date:  2003-01       Impact factor: 3.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.